Reducing LOS and Improving MI Diagnosis Using Guidance-Acceptable cTn Assays

15 Oct 2015
Reducing LOS and Improving MI Diagnosis Using Guidance-Acceptable cTn Assays

Katherine Soreng, PhD, Director of Clinical and Scientific Marketing at Siemens Healthcare Diagnostics, discusses the use of troponin as a marker of myocardial damage and its appropriate use in MI diagnosis. Learn how you can reduce length of patient stay and improve the earlier diagnosis of MI with guideline-acceptable assays.

Other videos from Siemens Healthineers

Links